BibSonomy :: publication ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

entry of kanefendt:

(0)

This publication has not been reviewed yet.

rating distribution

average user rating

The average rating is computed over all reviews. However, some of them may be invisible to you due to the visibility setting chosen by the reviewers.

(0.0 of 5.0 based on 0 reviews)

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer

by: S. E. Deprimo, C. Friece, X. Huang, J. Smeraglia, L. Sherman, M. Collier, C. Baum, A. D. Elias, H. J. Burstein, and K. D. Miller

In: J Clin Oncol Meeting Abstracts, Vol. 24, Nr. 18_suppl (2006) , p. 578.

Resources (URL, PDF, PS...)

URL:	http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578

578 Background: Sunitinib malate SU11248 is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an ~11% objective response rate Miller et al, ASCO 2005. To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 sVEGFR-2, soluble KIT sKIT, and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d

BibTeX record

@article{Deprimo.2006,
  abstract = {578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an [~]11% objective response rate (Miller et al, ASCO 2005). To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 (sVEGFR-2), soluble KIT (sKIT), and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d},
  added-at = {2010-02-05T11:28:39.000+0100},
  author = {Deprimo, S. E. and Friece, C. and Huang, X. and Smeraglia, J. and Sherman, L. and Collier, M. and Baum, C. and Elias, A. D. and Burstein, H. J. and Miller, K. D.},
  biburl = {http://www.bibsonomy.org/bibtex/2c051401322a1f486c5abd101be04bb7c/kanefendt},
  interhash = {78b24b80153edacd7fb67e831ddd9806},
  intrahash = {c051401322a1f486c5abd101be04bb7c},
  journal = {J Clin Oncol (Meeting Abstracts)},
  keywords = {Outcome Proteins Research SU11248 Treatment Tyrosine analysis methods protein response therapy},
  number = {18_suppl},
  pages = 578,
  timestamp = {2010-02-05T11:28:39.000+0100},
  title = {Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer},
  url = {http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578},
  volume = 24,
  year = 2006
}

Endnote record

%0 Journal Article
%1 Deprimo.2006
%A Deprimo, S. E.
%A Friece, C.
%A Huang, X.
%A Smeraglia, J.
%A Sherman, L.
%A Collier, M.
%A Baum, C.
%A Elias, A. D.
%A Burstein, H. J.
%A Miller, K. D.
%D 2006
%J J Clin Oncol (Meeting Abstracts)
%K 
%N 18_suppl
%P 578
%T Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer
%U http://meeting.jco.org/cgi/content/abstract/24/18_suppl/578
%V 24
%X 578 Background: Sunitinib malate (SU11248) is a multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activity that specifically inhibits VEGFR, PDGFR, KIT, RET and FLT3. In a phase II trial of 64 patients with refractory, metastatic breast cancer, sunitinib treatment resulted in an [~]11% objective response rate (Miller et al, ASCO 2005). To characterize potential biomarkers of biological response to sunitinib, we analyzed plasma levels of a panel of soluble proteins from patients in this trial. Methods: Patients received sunitinib in 6-week cycles comprised of 50 mg/day for 4 weeks followed by 2 weeks off treatment. Pre-dose plasma samples from 62 patients were obtained on days 1, 14, and 28 of the first cycle and days 1 and 28 of subsequent cycles. Plasma levels of VEGF, soluble VEGF receptor 2 (sVEGFR-2), soluble KIT (sKIT), and a novel biomarker, sVEGFR-3, were measured via ELISA analysis. Results: Plasma levels of each protein were modulated in most patients d